文献速递其他结缔组织病

原发性干燥综合征两种不同亚型的遗传与临床基础

Genetic and clinical basis for two distinct subtypes of primary Sjögren's syndrome.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究通过多中心靶向DNA测序(918例pSS患者和1264例对照)及临床数据分析,发现基于SSA/SSB抗体存在与否可将pSS分为两个临床亚组。HLA-DQA1位点在SSA/SSB阳性组中显示比值比6.10(95%CI:4.93, 7.54,P=2.2×10-62)的高风险关联,而抗体阴性组无此关联;MHC I类和II类最显著变异分别与高丙种球蛋白血症、白细胞减少、贫血、紫癜、主要唾液腺肿胀和淋巴结病风险升高相关。

要点

  • SSA/SSB抗体阳性与阴性pSS患者构成两个临床和遗传特征不同的亚组。
  • HLA-DQA1位点与SSA/SSB阳性pSS强关联,比值比6.10(95%CI:4.93, 7.54)。
  • MHC I类和II类变异与高丙种球蛋白血症、白细胞减少等腺外表现风险升高相关。

核心结论

  • 基于SSA/SSB抗体存在与否及HLA位点遗传标记,可定义具有不同临床表现的两个pSS亚组。

研究设计与样本

  • 在177例pSS患者和7672例对照中进行重复验证。

主要发现

  • 在HLA区域发现与pSS的强关联信号。
  • 临床数据主成分分析区分出以SSA/SSB抗体存在与否定义的两个患者亚组。
  • SSA/SSB阳性亚组中HLA-DQA1位点关联比值比为6.10(95%CI:4.93, 7.54,P=2.2×10-62),抗体阴性组中未观察到该关联。
  • MHC内观察到三个独立信号;MHC I类和II类中最显著的两个变异分别识别出高丙种球蛋白血症、白细胞减少、贫血、紫癜、主要唾液腺肿胀和淋巴结病风险较高的患者。
  • 重复验证证实MHC I类和II类信号关联仅限于SSA/SSB抗体阳性pSS。

临床怎么用

  • 在临床随访、药物开发和试验结局中应考虑SSA/SSB抗体定义的两个pSS亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Clinical presentation of primary Sjögren's syndrome (pSS) varies considerably. A shortage of evidence-based objective markers hinders efficient drug development and most clinical trials have failed to reach primary endpoints. METHODS: We performed a multicentre study to identify patient subgroups based on clinical, immunological and genetic features. Targeted DNA sequencing of 1853 autoimmune-related loci was performed. After quality control, 918 patients with pSS, 1264 controls and 107 045 single nucleotide variants remained for analysis. Replication was performed in 177 patients with pSS and 7672 controls. RESULTS: We found strong signals of association with pSS in the HLA region. Principal component analysis of clinical data distinguished two patient subgroups defined by the presence of SSA/SSB antibodies. We observed an unprecedented high risk of pSS for an association in the HLA-DQA1 locus of odds ratio 6.10 (95% CI: 4.93, 7.54, P=2.2×10-62) in the SSA/SSB-positive subgroup, while absent in the antibody negative group. Three independent signals within the MHC were observed. The two most significant variants in MHC class I and II respectively, identified patients with a higher risk of hypergammaglobulinaemia, leukopenia, anaemia, purpura, major salivary gland swelling and lymphadenopathy. Replication confirmed the association with both MHC class I and II signals confined to SSA/SSB antibody positive pSS. CONCLUSION: Two subgroups of patients with pSS with distinct clinical manifestations can be defined by the presence or absence of SSA/SSB antibodies and genetic markers in the HLA locus. These subgroups should be considered in clinical follow-up, drug development and trial outcomes, for the benefit of both subgroups.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Thorlacius GE, Hultin-Rosenberg L, Sandling JK, et al. Genetic and clinical basis for two distinct subtypes of primary Sjögren's syndrome. Rheumatology (Oxford). 2021. PMID: 32889544. doi:10.1093/rheumatology/keaa367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。